

Docket No. 4439-4044

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): **Masayuki NOGUCHI, Futoshi OKADA, and Shin HIROMURA**  
 Group Art Unit: **TBA**  
 Serial No.: **TBA**  
 Examiner: **TBA**  
 Filed: **HEREWITH**  
 For: **Akt ACTIVITY SPECIFICALLY INHIBITING POLYPEPTIDE**

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop PCT  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R.

§§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application.

The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:

AP20 Rec'd PCT/PTO 14 JUN 2006

- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
- ☒ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
- ☐ 37 C.F.R. §1.97(b)(4), before the mailing date of a first office action after the filing of an RCE under §1.114.

- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 4439-4044.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: June 14, 2006

By:



Kenneth H. Sonnenfeld // Michael A. Willis  
Reg. No. 33,285 // Reg. No. 53,913

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.  
3 World Financial Center  
New York, NY 10281-2101  
(212) 415-8700 Telephone  
(212) 415-8701 Facsimile



<b>FORM PTO-1449B</b>  <b>INFORMATION DISCLOSURE</b> <b>CITATION</b>		Attorney Docket: 4439-4044	Serial No.: TBA <b>10/583058</b>
		Applicant: Masayuki NOGUCHI, et al.	
		Filing Date: Herewith	Group Art Unit: TBA <b>14 JUN 2006</b>
		<b>AP20 Rec'd PCT/PTO</b>	
<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	1.	Marducci M. G. et al., "The Murine <i>TCL1</i> Oncogene: Embryonic And Lymphoid Cell Expression," <i>Oncogene</i> , No. 15, pgs. 919-926, (1997).	
	2.	Virgilio L. et al., "Identification Of The <i>TCL1</i> Gene Involved In T-cell Malignancies," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pgs. 12530-12534, (Dec.1994).	
	3.	Stern M.H. et al., "MTCP-1: A Novel Gene On The Human Chromosome Xq28 Translocated To The T Cell Receptor $\alpha/\delta$ Locus In Mature T Cell Proliferations," <i>Oncogene</i> No. 8, pgs. 2475-2483, (1993).	
	4.	Coffer P.J. et al, "Protein Kinase B (c-Akt): A Multifunctional Mediator Of Phosphatidylinositol 3-kinase Activation," <i>Biochem. J.</i> , No. 335, pgs. 1-13, (1998).	
	5.	Datta S. R. et al. "Cellular Survival: A Play In Three Acts," <i>Genes and Development</i> , No. 13, pgs. 2905-2927, (1999).	
	6.	Brunet A. et al. "Akt Promotes Cell Survival By Phosphorylating And Inhibiting A Forkhead Transcript Factor," <i>Cell</i> , Vol. 96, pgs. 857-868, (March 1999).	
	7.	Fruman D. A. et al. "Phosphoinositide Kinases," <i>Annu. Rev. Biochem.</i> , No 67, pgs. 481-507, (1998).	
	8.	Künstle G. et al., "Identification Of Akt Association And Oligomerization Domains Of The Akt Kinase Coactivator <i>TCL1</i> ," <i>Molecular And Cellular Biology</i> , pgs. 1513-1525, (March 2002).	
	9.	Laine J. et al., "The Protooncogene <i>TCL1</i> Is An Akt Kinase Coactivator," <i>Molecular Cell.</i> , Vol. 6, pgs. 395-407, (August 2000).	
	10.	Laine J. et al., "Differential Regulation Of Akt Kinase Isoforms By The Members Of The <i>TCL1</i> Oncogene Family," <i>The Journal of Biological Chemistry</i> , Vol. 277, No. 5, ppgs. 3743-3751, (February 2002).	
	11.	Obata T. et al., "Peptide And Protein Library Screening Defines Optimal Substrate Motifs For AKT/PKB," <i>The Journal of Biological Chemistry</i> , Vol. 275, No. 46, ppgs. 36108-36115, (November 17, 2000).	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.